Ignite Creation Date:
2024-05-06 @ 12:49 PM
Last Modification Date:
2024-10-26 @ 1:04 PM
Study NCT ID:
NCT03858972
Status:
TERMINATED
Last Update Posted:
2021-07-30
First Post:
2019-02-26
Brief Title:
Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative HR Positive LAMBC
Sponsor:
Odonate Therapeutics Inc
Organization:
Odonate Therapeutics Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-02-05
Start Date Type:
ACTUAL
Primary Completion Date:
2021-06-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-06-11
Completion Date Type:
ACTUAL
First Submit Date:
2019-02-26
First Submit QC Date:
February 28 2019
Study First Post Date:
2019-03-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-07-26
Last Update Post Date:
2021-07-30
Last Update Post Date Type:
ACTUAL